Raymond James on BridgeBio Pharma (BBIO): 'We expect continued strong commercial momentum for Attruby'
Tweet Send to a Friend
Raymond James analyst Martin Auster reiterated an Outperform rating and $89.00 price target on BridgeBio Pharma (NASDAQ: BBIO).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
